TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10615935

Group type: EXPERIMENTAL
Intervention: Laparoscopic ASGB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open ASGB
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 7852463

Group type: EXPERIMENTAL
Intervention: Short course of empiric therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to predisposing behaviors (urine retention, barrier contraception, inadequate fluid intake, poor hygiene)
Number of subjects: 0
Study: 1883793

Group type: EXPERIMENTAL
Intervention: Indomethacin (n = 11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nylidrin (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (23 pregnancies without uterine contractions)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Preterm birth group (12 women who gave birth preterm)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Full-term labour group
Number of subjects: 23
Study: 6805491

Group type: EXPERIMENTAL
Intervention: Fentanyl anaesthesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Innovar anaesthesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fentanyl and Innovar anaesthesia
Number of subjects: 18
Study: 31609898

Group type: EXPERIMENTAL
Intervention: Early cycled light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late cycled light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed feeding progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical feeding progression
Number of subjects: 0
Study: 29402253

Group type: EXPERIMENTAL
Intervention: Multi-component occupational rehabilitation program with added workplace intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-patient occupational rehabilitation program
Number of subjects: 0
Study: 26938920

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLF) 100 mg per day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (milk without bLF)
Number of subjects: 79
Study: 24268977

Group type: EXPERIMENTAL
Intervention: Beta-blockade (metoprolol)
Number of subjects: 26
Study: 21443612

Group type: EXPERIMENTAL
Intervention: Test group 1 (T(1), implant diameter 4.3 mm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Test group 2 (T(2), implant diameter 4.8 mm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Test group 3 (T(3), implant diameter 5.5 mm)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (implant diameter 3.8 mm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adjacent teeth
Number of subjects: 26
Study: 20813541

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using phthalocyanine derivatives as photosensitizers in group L (liposomes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) in group L (liposomes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) in group N (nanoemulsions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (contralateral tooth not treated with PDT)
Number of subjects: 16
Study: 17003366

Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane (high-risk patients)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Doxorubicin without dexrazoxane (high-risk patients)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Intensive intrathecal chemotherapy (standard-risk patients)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Cranial radiation (standard-risk patients)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase (all patients)
Number of subjects: 491

Group type: COMPARATOR
Intervention: E. coli asparaginase (all patients)
Number of subjects: 491
Study: 16506860

Group type: EXPERIMENTAL
Intervention: INT (2 x 15 min.d(‐1) exercise program)
Number of subjects: 37

Group type: COMPARATOR
Intervention: CON (1 x 30 min.d(‐1) exercise program)
Number of subjects: 37
Study: 14636505

Group type: EXPERIMENTAL
Intervention: PEPAF intervention (physical activity plan designed by doctors)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Control group (no systematic intervention on exercise until after 2005)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: PEPAF intervention
Number of subjects: 7000
Study: 10946879

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8833204

Group type: EXPERIMENTAL
Intervention: Osteoporotic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 1468460

Group type: EXPERIMENTAL
Intervention: Airway pressure monitor
Number of subjects: 10

Group type: COMPARATOR
Intervention: MR10 respiration monitor
Number of subjects: 10
Study: 6388586

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 12
Study: 29677227

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 24
Study: 29926787

Group type: EXPERIMENTAL
Intervention: Flash-tip catheter (SurFlash Plus, Terumo Medical Corporation)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control catheter (Insyte Autoguard; Becton, Dickinson and Company)
Number of subjects: 600
Study: 27144955

Group type: EXPERIMENTAL
Intervention: Balance and Plyometric Training (BPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plyometric and Balance Training (PBT)
Number of subjects: 24
Study: 24474180

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1.0 mL (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 0.8 mL (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 0.6 mL (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 60
Study: 22350323

Group type: EXPERIMENTAL
Intervention: Maoto
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 28
Study: 20308670

Group type: EXPERIMENTAL
Intervention: Trastuzumab with chemotherapy (EC-T[X])
Number of subjects: 445

Group type: COMPARATOR
Intervention: Reference group (HER2-negative tumors treated with the same chemotherapy without trastuzumab)
Number of subjects: 445
Study: 17296641

Group type: EXPERIMENTAL
Intervention: MINO (portable nitric oxide analyzer)
Number of subjects: 151

Group type: COMPARATOR
Intervention: NIOX (laboratory-based analyzer)
Number of subjects: 151
Study: 16119520

Group type: EXPERIMENTAL
Intervention: Arabic version of the Zung Self-Rating Depression Scale
Number of subjects: 240

Group type: COMPARATOR
Intervention: English version of the Zung Self-Rating Depression Scale
Number of subjects: 240
Study: 12100089

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg rizatriptan
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 16
Study: 10396791

Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 7485936

Group type: EXPERIMENTAL
Intervention: PCA + C (continuous infusion of morphine 1 mg/hr)
Number of subjects: 96

Group type: COMPARATOR
Intervention: PCA (normal saline infusion)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PCA + C
Number of subjects: 96

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 96
Study: 2290601

Group type: EXPERIMENTAL
Intervention: Synthetic diosmin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-treated cases
Number of subjects: 120
Study: 6179738

Group type: EXPERIMENTAL
Intervention: 50 msec white noise pips at intensities ranging from 55 to 115 dB SPL
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Attention conditions (counting stimuli, ignoring stimuli, visual search task)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stimulus intensity of 80 to 110 dB with a probability of 0.25 for 110 dB
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 115 dB noise pips presented at random intervals between 10 and 90 sec
Number of subjects: 3
Study: 30252061

Group type: EXPERIMENTAL
Intervention: DMAU 400 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control 400 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DMAU (various doses: 0, 100, 200, 400 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DMAU
Number of subjects: 100
Study: 28511660

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg once daily for up to 28 days)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo (identical tablets for up to 28 days)
Number of subjects: 540
Study: 26091830

Group type: COMPARATOR
Intervention: Ropivacaine 0.50% (30 cc) + placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 μg/kg
Number of subjects: 80
Study: 24834935

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV)
Number of subjects: 109
Study: 22496101

Group type: EXPERIMENTAL
Intervention: Oral Losec MUPS for a period of 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose vitamin C tablet for a period of 2 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison between the two groups
Number of subjects: 40
Study: 19327949

Group type: EXPERIMENTAL
Intervention: Hypercapnia group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normocapnia group (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17335366

Group type: EXPERIMENTAL
Intervention: Subgingival chlorhexidine (CHX) varnish administration
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions and same-day full-mouth root planing)
Number of subjects: 33
Study: 15204012

Group type: EXPERIMENTAL
Intervention: 1 mg xaliproden
Number of subjects: 2077

Group type: EXPERIMENTAL
Intervention: 2 mg xaliproden
Number of subjects: 2077

Group type: EXPERIMENTAL
Intervention: 1 mg xaliproden with riluzole
Number of subjects: 2077

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2077
Study: 12226965

Group type: EXPERIMENTAL
Intervention: Behavioral strategy to enhance adherence to daily monitoring
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 9843529

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (beta-estradiol 2 mg/tablet, 3 tablets/day for 3 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 21
Study: 8305322

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment applied twice daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3059274

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg/day and Penicillin 3 M UI/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cephalothin 250 mg, Gentamicin 20 mg, and Bacitracin 150 UI
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pefloxacin and Penicillin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cephalothin, Gentamicin, and Bacitracin
Number of subjects: 65
Study: 31028614

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 181
Study: 29134426

Group type: EXPERIMENTAL
Intervention: Amenamevir 300 mg (single and multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amenamevir 600 mg (single and multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amenamevir (various doses, 5-2400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amenamevir with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet formulation of Amenamevir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amenamevir (various doses)
Number of subjects: 0
Study: 25284453

Group type: EXPERIMENTAL
Intervention: Anaesthetic digital block with epinephrine (2% mepivacaine with 1:100,000 epinephrine)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tourniquet with anaesthetic digital block without epinephrine (2% mepivacaine without epinephrine)
Number of subjects: 44
Study: 24491880

Group type: EXPERIMENTAL
Intervention: 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21396703

Group type: EXPERIMENTAL
Intervention: Insulin degludec three times a week (starting dose 20 U per injection)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Insulin degludec once a day (starting dose 10 U; group A)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Insulin degludec once a day (starting dose 10 U; group B)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Insulin glargine once a day (starting dose 10 U)
Number of subjects: 245
Study: 19905945

Group type: EXPERIMENTAL
Intervention: Experimental combined regenerative therapy (ET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 60
Study: 16510646

Group type: EXPERIMENTAL
Intervention: Intervention group (decreased SSB consumption)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no change in SSB consumption)
Number of subjects: 103
Study: 14628982

Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine (paroxetine CR) up to 50 mg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Immediate-release paroxetine (paroxetine IR) up to 40 mg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 15022536

Group type: EXPERIMENTAL
Intervention: Dipyrone preoperatively
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dexamethasone and dipyrone preoperatively
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (Dipyrone only)
Number of subjects: 14
Study: 10995147

Group type: EXPERIMENTAL
Intervention: Combined rectus sheath and ilioinguinal blocks with bupivacaine 0.25% with adrenaline 1:400,000, up to 60 ml depending on patient's weight.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined rectus sheath and ilioinguinal blocks
Number of subjects: 37
Study: 7783888

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) treatment
Number of subjects: 11
Study: 2213636

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day) administered at 7 a.m.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day) administered at 11 p.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (light therapy not specified in the abstract)
Number of subjects: 0
Study: 352200

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine 4.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine 9 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 24
Study: 31014369

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 45
Study: 28516342

Group type: EXPERIMENTAL
Intervention: Oxycodone 10-mg product under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxycodone 10-mg product under fed conditions
Number of subjects: 24
Study: 25375652

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 909

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50 mg/d and 100 mg/d)
Number of subjects: 909
Study: 23709010

Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy (HILT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exercise group (Control)
Number of subjects: 48
Study: 22524834

Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy (TP) group (Taxotere 35 mg/m2 once weekly, Cisplatin 20 mg/m2 once weekly)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT) group
Number of subjects: 56
Study: 19602880

Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg
Number of subjects: 332

Group type: COMPARATOR
Intervention: N-ER 1 g (Niaspan(R))
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 17331753

Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (EMLA) cream
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (Oraqix) gel
Number of subjects: 40
Study: 15672120

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 2000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (both dosages)
Number of subjects: 0
Study: 11988029

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation of infant formulas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention trials extending beyond the first two years of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to selection and attrition biases
Number of subjects: 0
Study: 9541154

Group type: EXPERIMENTAL
Intervention: 75 mg/day venlafaxine
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 225 mg/day venlafaxine
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 375 mg/day venlafaxine
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 8014524

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Reconstituted lyophilized PRP-T vaccine
Number of subjects: 10000

Group type: COMPARATOR
Intervention: PRP-T vaccine
Number of subjects: 10000
Study: 2600748

Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater allografts (FDDMA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Host flap (RF)
Number of subjects: 7
Study: 28750968

Group type: EXPERIMENTAL
Intervention: Standard push-up plus (SPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wall push-up plus (WPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isometric horizontal abduction (IHA) application during SPP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isometric horizontal abduction (IHA) application during WPP
Number of subjects: 15
Study: 26447350

Group type: EXPERIMENTAL
Intervention: Crystalline short-chain α-glucan (CSCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Waxy maize starch
Number of subjects: 10
Study: 23416219

Group type: EXPERIMENTAL
Intervention: Restorative home care services (goal facilitation tool, individually tailored activity programs)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care (standard needs assessment)
Number of subjects: 205
Study: 21204607

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CTX) 3.0 mg
Number of subjects: 6
Study: 18762208

Group type: EXPERIMENTAL
Intervention: NHTG2 (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NHTG1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicorette FreshMint
Number of subjects: 0
Study: 17382162

Group type: EXPERIMENTAL
Intervention: Two-suture anastomosis technique (group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Four-suture anastomosis technique (group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Six-suture anastomosis technique (group 3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 15619966

Group type: EXPERIMENTAL
Intervention: Pericardial suction blood (PSB) using conventional cardiotomy suction retransfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pericardial suction blood (PSB) after cell-saver processing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 11204294

Group type: EXPERIMENTAL
Intervention: Indexation of left ventricular mass using bioelectrical impedance-determined fat-free mass (FFM)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Indexation of left ventricular mass using approximated fat-free mass (FFMa)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Gender-specific equations for predicting FFM
Number of subjects: 1371
Study: 9593024

Group type: EXPERIMENTAL
Intervention: Vaccine group (2 doses of whole, killed promastigote vaccine cocktail plus BCG adjuvant)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Control group (2 doses of BCG only)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 844

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 844
Study: 7821196

Group type: EXPERIMENTAL
Intervention: Wrist-Erb point conduction velocity (WECV)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: EP-N13 interpeak latency
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation between WECV and EP-N13 interpeak latency
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: WECV correlation with motor and sensory peripheral nerve conduction velocities
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation between peripheral parameters and EP-N13 interpeak latency
Number of subjects: 38